MW-189 is under clinical development by ImmunoChem Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect MW-189’s likelihood of approval (LoA) and phase transition for Hemorrhagic Shock took place on 03 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their MW-189 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
MW-189 is under development for the treatment of for the treatment of Alzheimer's disease (AD), aneurysmal subarachnoid hemorrhage, rheumatoid arthritis (RA), intracerebral hemorrhage (ICH), traumatic brain injury (TBI) and neuropathic pain. The drug candidate is administered by intravenous injection or orally. The drug candidate acts by targeting the overproduction of inflammatory cytokines, such as interleukin-1 (IL-1beta), tumour necrosis factor-alpha (TNF-alpha).
Quick View MW-189 LOA Data
|Highest Development Stage|